BioMarin Reports Record $3.22 Billion in Revenue for Q4 and Full Year 2025
BioMarin (BMRN) reported record total revenues of $3.22 billion for the full year 2025, a 13% increase driven by strong growth across enzyme therapies (+9%) and Voxzogo (+26%). The company highlighted its strategic achievements in operational excellence and cash flow generation while preparing to expand through two major acquisitions announced last year.
Tickers: $BMRN
Topics: acquisitions biotech enzyme_therapies revenue_growth